Two biomarkers with known clinical relevance, such as tumor PD-L1 expression and the number of neo-antigen–specific T cell clones, were among the best 30 biomarker candidates identified, as both achieved a response probability of approximately 0.5. Here, CD274 is linked to neoplasm.